by the delivery device chosen. Close follow-up of patients will be required with readjustment of doses at intervals of two to four weeks in order to identify the lowest dose of inhaled corticosteroids that provides optimal control of symptoms and lung function. Given the rapid onset of bronchodilation with the short-acting beta-agonists and their prescription on an as-needed basis, choosing an equivalent and effective dose will likely be much less difficult .
The therapeutic armamentarium for the treatment of asthma is increasing in both effectiveness and complexity. Deriving the most benefit from available drug therapy will require close collaboration between patients and their physicians, and this collaboration is likely to be most effective with the availability of a structured educational intervention.